GlassScriptPhysician profile
Paul S Lee
NPI 1760531693
$16,614.23
in general payments reported to CMS, 2019-2025
48 companies · $3,033 in 2025
The $3,033 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,898 · 2020: $2,412 · 2021: $1,440 · 2022: $2,238 · 2023: $2,847 · 2024: $2,748 · 2025: $3,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,607 · Education: $20.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,607.07 |
| Education | $20.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,929.36 | 2019-2025 | |
| Pentax of America, INC. | $1,511.75 | 2020 | |
| Janssen Biotech, INC. | $1,365.09 | 2019-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $977.46 | 2019-2025 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $849.94 | 2019-2025 | Entyvio, Eohilia |
| Aimmune Therapeutics, INC. | $696.62 | 2024-2025 | Zenpep, Vowst |
| Genzyme Corporation | $598.48 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $552.09 | 2022-2025 | Dupixent |
| Boston Scientific Corporation | $451.19 | 2019-2024 | Bodyguardian, Spyglass |
| Nestle Healthcare Nutrition INC. | $450.41 | 2021-2023 | |
| Madrigal Pharmaceuticals | $369.85 | 2025 | Rezdiffra |
| Celgene Corporation | $369.13 | 2021-2024 | Zeposia |
| Pfizer INC. | $259.28 | 2019-2024 | |
| Gilead Sciences, INC. | $203.08 | 2019-2025 | |
| Medtronic USA, INC. | $169.55 | 2020 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.